How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about palopegteriparatide

Marketing authorisation indication

2.1

Palopegteriparatide (Yorvipath, Ascendis Pharma) is 'a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism'.

Dosage in the marketing authorisation

Price

2.3

The list price is £7,406.00 per pack of 2 pre-filled multiuse disposable injection pens (excluding VAT; BNF online accessed October 2025). Pens are available in different doses.

2.4

The company has a commercial arrangement, which would have applied if palopegteriparatide had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Ascendis Pharma will be included here when guidance is published.